



Suppression of induction of experimental immune mediated blepharoconjunctivitis by tolerogenic conjugates of the antigen and monomethoxypolyethylene glycol

Atsuki Fukushima, Koji Nishino, Hironori Yoshida, et al.

Br J Ophthalmol 1999 83: 973-979

doi: 10.1136/bjo.83.8.973

Updated information and services can be found at:

<http://bjo.bmj.com/content/83/8/973.full.html>

These include:

References

This article cites 19 articles, 7 of which can be accessed free at:

<http://bjo.bmj.com/content/83/8/973.full.html#ref-list-1>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic collections

Articles on similar topics can be found in the following collections

[Conjunctiva](#) (151 articles)

[Ocular surface](#) (379 articles)

Notes

To order reprints of this article go to:

<http://bjo.bmj.com/cgi/reprintform>

To subscribe to *British Journal of Ophthalmology* go to:

<http://bjo.bmj.com/subscriptions>

Suppression of induction of experimental immune mediated blepharoconjunctivitis by tolerogenic conjugates of the antigen and monomethoxypolyethylene glycol

Atsuki Fukushima, Koji Nishino, Hironori Yoshida, Masaru Takata, Hisayuki Ueno

Abstract

Aim—Covalent conjugates consisting of diverse antigens coupled to optimal numbers of monomethoxypolyethylene glycol (mPEG) molecules have been shown to suppress antigen specific antibody formation. In this study, the possibility was examined that the same conjugates might prevent experimental immune mediated blepharoconjunctivitis (EC, formerly EAC) which had been shown to be caused by CD4⁺ T cells—that is, to cell mediated immunity.

Methods—6–8 week old male Lewis rats were used. The test groups of rats received two intravenous injections, each of 300 µg, of a conjugate of ovalbumin mPEG (OVA(mPEG)₁₁) in phosphate buffered saline (PBS), 14 and 28 days before the single immunisation with OVA in complete Freund's adjuvant. The rats were challenged 3 weeks later by eye drops containing OVA; 24 hours later they were sacrificed, and their eyes, blood, and lymph nodes were harvested for histological examination and determination of anti-OVA antibody titres and levels of cellular immunity. Two control groups received PBS or OVA in PBS before immunisation. Furthermore, the possibility that OVA(mPEG)₁₁ may have induced OVA specific suppressor cells was tested by establishing the effects of the co-transfer of splenocytes from OVA(mPEG)₁₁ treated rats with OVA primed lymph node cells on the manifestations of EC.

Results—Either PBS or OVA pretreated rats, which had not received OVA(mPEG)₁₁, developed high levels of antibodies and cell mediated immune responses to OVA, and application of eye drops led to blepharoconjunctivitis with massive cellular infiltration. In contrast, pretreatment with OVA(mPEG)₁₁ prevented cellular infiltration into the lids and conjunctivas, as well as the formation of detectable humoral and cellular immunity against OVA. Co-transfer of splenocytes from OVA(mPEG)₁₁ treated rats with OVA primed lymph node cells suppressed the cellular infiltration on application of OVA on the conjunctiva.

Conclusions—These data indicate that intravenous injection of OVA(mPEG)₁₁ conjugates suppressed both humoral and cellular immunity by the effects of antigen

specific suppressor cells, thus leading to the inhibition of development of EC.

(Br J Ophthalmol 1999;83:973-979)

Induction of antigen specific immunological tolerance is a most attractive strategy for treating the corresponding immunological diseases. Among experimental immunological therapeutic strategies, one may cite treatment with monoclonal anti-CD4 antibodies,¹ antigen feeding,² or injection of peptides representing the epitopes of the autoantigen in question.³ In addition to the encouraging results in animals, some of these procedures were demonstrated to be also effective in patients.^{4,5}

Obviously antigen specific suppression of deleterious immune responses is to be preferred over the other procedures. In fact, suppression of primary immune responses has been achieved by different procedures—for example, by intravenous injection of (i) massive doses of aggregate free antigen,⁶ (ii) conjugates of antigen and autologous γ globulins,⁷ (iii) recently by conjugates of the antigens in question and optimal numbers of molecules of polyethylene glycol (PEG).⁸

We established a disease model of blepharoconjunctivitis in Lewis rats utilising ovalbumin (OVA) as a model non-ocular antigen and termed experimental immune mediated blepharoconjunctivitis (EC, formerly EAC).⁹ This disease is transferable by *in vitro* stimulated lymph node cells from OVA primed rats^{9,10} as well as OVA specific CD4⁺ T cell line,¹¹ whereas little, if any, IgE was detected in serum from antigen primed rats. In addition, a large amount of IFN-γ was produced by lymph node cells and this cell line.¹¹ These data indicated that EC is caused by Th1 type CD4⁺ T cells (and/or IgG antibodies), while IgE is not involved in the induction of EC.

Until recently, antigen monomethoxypolyethylene glycol (mPEG) conjugates have been used for specific suppression of antibody responses. However, in this study we demonstrated that antigen-(mPEG)₁₁ conjugates were also capable of suppressing cellular responses. Hence, having established that cellular immunity was dominantly involved in both induction and effector phases of EC in rats,^{9,10} we investigated in the present study the effects of tolerogenic mPEG conjugates of the same antigen—that is, OVA, on the suppression of cell mediated blepharoconjunctivitis.

Department of
Ophthalmology, Kochi
Medical School,
Nankoku City, Japan
A Fukushima
K Nishino
H Yoshida
H Ueno

Department of
Immunology, Kochi
Medical School,
Nankoku City, Japan
M Takata

Correspondence to:
Atsuki Fukushima,
Laboratory of Immunology,
Department of
Ophthalmology, Kochi
Medical School, Kohasu,
Okochi-cho, Nankoku
783-8505, Japan.

Accepted for publication
15 March 1999




Figure 1 Experimental protocol. Groups of two to three rats were injected intravenously twice with 300 µg of OVA, OVA(mPEG)₁₁, or PBS, 14 and 28 days before immunisation with 100 µg of OVA in CFA. Three weeks after immunisation they were challenged by the ocular route with OVA by eye drops, and 1 day later they were sacrificed, and their organs were used for assays.

Materials and methods

RATS

Six to 8 week old male Lewis rats were purchased from Seac Yoshitomi, Fukuoka, Japan and were maintained in a pathogen-free animal facility at Kochi Medical School. All animal procedures conformed to institutional guidelines and to the ARVO resolution on use of animals in research.

PREPARATION OF THE TOLERAGEN BY COUPLING OVA TO MPEG

For the present study, mPEG (MW 5000) activated with cyanuric chloride and OVA (grade V) were purchased from Sigma Immunochemicals (St Louis, MO, USA) and converted to the corresponding conjugate (OVA(mPEG)₁₁) using cyanuric chloride as the coupling agent, according to the procedure reported previously.¹² There was no difference in endotoxin level between OVA and OVA(mPEG)₁₁ (2.3 ng/ml).

SYNTHETIC OVA OVERLAPPING PEPTIDES

Thirty eight overlapping 15-mer peptides, spanning the entire OVA sequence, were synthesised following the multipin method¹³ based on the amino acid sequence of OVA (Peptide Institute, Inc, Osaka, Japan). Each peptide overlaps five amino acids.

IMMUNISATION

Each rat received in the left hind foot pad an injection of 100 µl containing 100 µg of OVA emulsified in complete Freund's adjuvant (CFA, Yatron, Tokyo, Japan). In some experiments, bovine serum albumin (BSA, Sigma Immunochemicals, St Louis, MO, USA) was used instead of OVA as both immunising and challenging antigen at the same dose and concentration to test whether the suppression is antigen specific or not.

EXPERIMENTAL PROTOCOL FOR TESTING THE IMMUNOSUPPRESSIVE CAPACITY OF OVA(MPEG)₁₁

Pretreatment of rats with OVA(mPEG)₁₁

Figure 1 illustrates the experimental procedure used. Each rat received intravenously two injections of 500 µl, each containing 300 µg of OVA(mPEG)₁₁, 28 and 14 days before immunisation; each of two groups of control rats received 500 µl of PBS or 300 µg of immunising OVA in the same volume. Three weeks after

immunisation, all rats were challenged with a total of 250 µg of OVA by 50 µl of eye drops, each drop consisting of a solution of 5 mg of OVA per ml of PBS. Each group consisted of three rats in each experiment and each experiment was repeated four times.

Effects of splenocytes from OVA(mPEG)₁₁ treated rats on the induction of EC in rats receiving lymph node cells from third party immunised rats

Cells from inguinal lymph nodes of OVA primed rats were harvested between 14 and 21 days after immunisation. These cells (100×10^6) were cultured for 3 days in 25 cm² flask (Nunc, Roskilde, Denmark) containing 10 ml of RPMI1640 medium (Nikken, Osaka, Japan) supplemented with 2 mM L glutamine, 5×10^{-5} M 2-mercaptoethanol (2-ME), 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µg/ml OVA, and 10% fetal calf serum (FCS, ICN Biomedical Japan Co, Tokyo, Japan). At the end of the 3 day period, the stimulated cells were harvested and washed three times.^{9, 10} The stimulated cells (30×10^6) were injected intravenously into syngeneic recipients either with 200×10^6 of splenocytes from naive rats, or from rats which had been treated with OVA(mPEG)₁₁. As described in the preceding paragraph, 4 days later the recipients' eyes were challenged by eye drops of the OVA solution, and 24 hours later their eyes were enucleated for histological examination.

COUNT OF INFILTRATED CELLS IN THE CONJUNCTIVA

After clinical evaluation, the eyes including the lids were fixed in 10% buffered formalin and embedded in paraffin. Thick sections of 10 µm were stained with haematoxylin and eosin, and the infiltrated cells were counted in the palpebral conjunctiva with an eye piece grid of 400× magnification.^{9, 10}

ASSESSMENT OF CELLULAR RESPONSES

Cellular responses of immunised rats were measured by the lymphocyte proliferation assay. For each experiment, lymph nodes of each group of rats were combined. Lymphocyte proliferation assays were performed in quadruplicate utilising 96 flat bottom well plates. Lymph node cells (3×10^5 cells/well) were cultured in a final volume of 0.2 ml RPMI medium supplemented with 5% FCS. The cells were stimulated with (i) OVA or OVA(m-




Figure 2 Histological sections of the conjunctiva from rats pretreated with PBS (A, B), OVA(mPEG)₁₁ (C, D), or OVA (E, F). Sections were stained with haematoxylin and eosin. Magnifications were either $\times 160$ (A, C, E) or $\times 320$ (B, D, F).

PEG)₁₁ at concentrations of 0.1, 1, 10, 100 $\mu\text{g/ml}$, (ii) synthetic OVA overlapping peptides at 20 $\mu\text{g/ml}$, and (iii) purified protein derivatives (PPD, Japan BCG, Tokyo, Japan) at 5 $\mu\text{g/ml}$. After incubation of 72 hours at 37°C in a humidified atmosphere with 5% carbon dioxide, the cultures were pulsed for 16 hours with 0.5 $\mu\text{Ci/well}$ of ^3H -thymidine (Japan Atomic Energy Research Institute, Tokai,

Japan). The cultured cells were then harvested and their radioactivity was measured. The data are expressed as stimulation indices (SI = mean cpm in stimulated cultures/mean cpm in unstimulated control cultures) or delta cpm (mean cpm in stimulated cultures - mean cpm in unstimulated control cultures). In addition to cellular proliferative responses, production of IFN- γ and IL-4 by stimulation with OVA in the culture supernatant of lymph node cells from three different groups were tested using commercial cytokine ELISA (BioSource International, Camarillo, CA, USA) detailed in previous reports.^{10 11}




Figure 3 The infiltrated cell number refers to the average of infiltrated cells in the palpebral conjunctiva of rats treated with OVA, OVA(mPEG)₁₁, or PBS. The error bars indicate standard errors. Each group consisted of 12 rats.

ASSESSMENT OF HUMORAL RESPONSES

Serum was collected from each rat via cardiac puncture at the time of sacrifice, and serum levels of anti-OVA antibodies were determined by direct ELISA. Briefly, OVA (500 ng/well) was adsorbed on to 96 well plates for 2 hours at 37°C. The plates were washed with PBS-Tween and serially diluted serum samples were added to the wells. Thereafter, the plates coated with the antibody were treated with peroxidase conjugated anti-rat IgG and washed




Figure 4 Proliferative response to OVA by lymph node cells of rats pretreated with OVA(mPEG)₁₁, OVA, or PBS, and immunised with OVA. The draining lymph node cells were harvested and tested for their capacity to proliferate. The recorded data represent means of the values of stimulation indices (SI) of cells of three rats of each group. Similar results were obtained in three confirmatory experiments. The combined mean cpm values in the unstimulated control cultures of rats were between 465 and 503.

before addition of the substrate, 3,3',5,5'-tetramethylbenzidine base (TMB-ELISA, Gibco BRL, Gaithersburg, MD, USA); finally the optical densities (ODs) of the contents of all wells were determined at 610 nm. For detecting OVA specific IgE, the passive cutaneous anaphylaxis (PCA) method¹⁴ was used.

STATISTICAL ANALYSIS

Statistical comparison in each group was performed by Student's *t* test.

Results

INHIBITION OF DISEASE INDUCTION

As previously reported,⁹ the main feature of EC is mononuclear cellular infiltration in the conjunctiva. The severity of EC has been assessed by counting infiltrated cells in the

palpebral conjunctiva, because severity of clinical grading was in parallel with the infiltrated cell number.⁹ As shown in Figure 2, massive cellular infiltration was demonstrated in PBS and OVA treated rats, while minimal inflammatory cells were detected in OVA(mPEG)₁₁ treated rats. The number of cells infiltrated on challenge with OVA into the palpebral conjunctivae of rats, which had been pretreated with PBS, OVA, or OVA(mPEG)₁₁, are shown in Figure 3. The infiltrated cell number of the group with OVA (average infiltrated cell number (n)=113) was almost identical to that of the control group (n=120). By contrast, however, n for the group treated with OVA(mPEG)₁₁ was only 22—that is, it was significantly lower than that for the two other groups (*p*<0.01). No differences in inflammatory cell numbers in the conjunctiva among three groups of different treatment were detected in cases where BSA was used as an immunising and challenging antigen (data not shown).

INHIBITION OF CELLULAR AND HUMORAL RESPONSES IN RATS PRETREATED WITH OVA(mPEG)₁₁

To investigate the effects of treatment of OVA(mPEG)₁₁ on the immune responses, we tested the levels of (i) cellular immunity by the proliferation assay or cytokine production (IFN- γ and IL-4) of lymph node cells, and (ii) antibody responses by ELISA or PCA using the sera. Representative data of three rats per group were presented in Figures 4–6. Both cellular proliferation (Figs 4 and 5) and IgG production (Fig 6A) in response to OVA were depressed in rats pretreated with OVA(mPEG)₁₁, in relation to the levels of rats treated with OVA or PBS. Inhibition of proliferative responses was remarkable in immunodomi-




Figure 5 Proliferative response to OVA peptides by lymph node cells of rats pretreated with OVA(mPEG)₁₁ or PBS, and immunised with OVA. The recorded data represent means of the values of stimulation indices (SI) of cells of two rats of each group. Similar results were obtained in one more experiment. The combined mean cpm values in the unstimulated control cultures of rats were 950 (PBS) and 1130 (OVA(mPEG)₁₁).




Figure 6 (A) Measurement of OVA specific IgG by ELISA in serum of rats pretreated with OVA(mPEG)₁₁, OVA, or PBS, and immunised with OVA. The sera were collected at the time of sacrifice and assayed by ELISA. The abscissa indicates the degree of dilution of the serum; the ordinate represents absorbance at 610 nm. Similar results were obtained in three other separate experiments. (B) Proliferative responses against PPD by lymph node cells of rats pretreated with OVA(mPEG)₁₁, OVA, or PBS, and subsequently immunised with OVA. Except for using PPD instead of OVA, the procedure used was the same as employed for the experiment illustrated in Figure 4; in addition, the concentration of PPD was 5 µg/ml. (C) Production of IFN-γ in the culture supernatant of OVA primed lymph node cells from rats pretreated with OVA(mPEG)₁₁, OVA, or PBS by *in vitro* stimulation with OVA. Y axis indicates the produced amount of IFN-γ (pg/ml).

nant epitopes (Fig 5). There were a few epitopes which exhibited higher stimulatory effects in response to OVA(mPEG)₁₁ treated cells than PBS treated cells (Fig 5). By contrast, no significant differences in proliferative responses to PPD were noted among three groups (0.248 < p < 0.480) (Fig 6B). Lymph node cells from all three groups did not exhibit any apparent proliferative responses against




Figure 7 Infiltrated cell number in the palpebral conjunctivas of rats which received stimulated OVA primed cells, and either naive splenocytes or splenocytes from rats pretreated with OVA(mPEG)₁₁ and subsequently treated with OVA in CFA (Fig 1). Stimulated OVA primed cells were transferred into recipients with splenocytes from either naive rats or rats treated with OVA(mPEG)₁₁. Four days after cell transfer, the rats were challenged and 24 hours later they were sacrificed for counting infiltrated cells in the conjunctiva.

OVA(mPEG)₁₁ (data not shown). In addition to cellular proliferative responses, production of IFN-γ in the culture supernatant was suppressed in OVA(mPEG)₁₁ treated groups compared with the other two groups (p < 0.01) (Fig 6C). It is of note that IL-4 and IgE were below detectable levels by the assays used here in all three groups (data not shown).

CO-TRANSFER OF SPLENCYTES OF OVA(mPEG)₁₁ TREATED RATS SUPPRESSED THE INDUCTION OF EC BY TRANSFER OF OVA PRIMED LYMPH NODE CELLS

To analyse the mechanism of tolerance induced by treatment with OVA(mPEG)₁₁, splenocytes from OVA(mPEG)₁₁ treated rats were passively transferred together with OVA primed lymph node cells, as outlined in the Materials and methods section. The data clearly show that the co-transfer of OVA(mPEG)₁₁ treated splenocytes suppressed the influx of inflammatory cells into the conjunctiva compared with the co-transfer of splenocytes from naive rats (p = 0.040) (Fig 7).

Discussion

The published studies to date support the conclusion that administration of a conjugate of a given antigen and an optimal number of mPEG molecules induces suppression of antibodies specific to the antigen in question. As reported previously,⁹ in our experimental model of blepharoconjunctivitis, cellular immunity, especially Th1 type cell mediated immunity, appeared to be essential both in the induction and effector phases of this disease. Hence, the aim of this study was to investigate the possibility that administration of mPEG conjugates of the corresponding antigen would inhibit both the induction of antigen specific cellular immunity and the consequent development of the disease.

Indeed, the results of this study supported the conclusion that pretreatment of rats with OVA(mPEG)₁₁ downregulated the induction of

both cellular and humoral immunity to OVA (Figs 4–6), and consequently inhibited development of OVA specific EC (Figs 2 and 3). To test the possibility that the tolerance demonstrated here by OVA(mPEG)₁₁ treatment might be due to a change in the presentation of peptides, proliferative responses against OVA fragments were performed to compare with those treated with PBS. No fragments were selected to be stimulatory for lymph node cells from OVA(mPEG)₁₁ treated rats (Fig 5), indicating that this suppression may not be epitope specific but rather protein specific. Interestingly, OVA(mPEG)₁₁ did not have stimulatory effects to lymphocytes sensitised with OVA from rats pretreated with OVA(mPEG)₁₁ intravenously. It is important to point out that whereas in vitro proliferative responses to OVA of lymph node cells from OVA(mPEG)₁₁ treated rats were inhibited, the reactivity of these cells to PPD was the same as that of lymph node cells from OVA treated rats or from the control group (Fig 6A). In addition, the results that pretreatment with OVA(mPEG)₁₁ did not suppress inflammatory cellular infiltration in the conjunctiva when a third party antigen BSA was used as an immunising and challenging antigen, further support the conclusion that antigen-mPEG conjugates suppress the immune response in an antigen specific manner.

Although some reports claim that intravenous injection of native antigen could induce tolerance,^{15 16} this statement is not supported by our attempt to induce tolerance by injection of the native antigen, OVA (Figs 4–6). Since this effect may be dependent on the dose and/or the physical state of antigens injected, we investigated the effect of different doses by intravenous injection of OVA, 2 µg, 200 µg, and 20 mg, in three groups of rats, following the protocol shown in Figure 1. No differences in either proliferative responses or disease gradings (data not shown) were observed among these three groups in relation to the control group treated with PBS. Therefore, it is clear that it is difficult, if at all possible, to induce tolerance by pretreatment with OVA, compared with the successful suppression of the antigen specific immune response by mPEG antigen conjugates.

Recently, it was demonstrated that the development of diseases induced by Th1 type immune responses such as experimental autoimmune uveoretinitis (EAU) could be inhibited by augmentation of antigen specific Th2 type immune responses.^{17 18} To investigate the possible involvement of augmentation of OVA specific Th2 type immunity by OVA(mPEG)₁₁ treatment, IL-4 production by lymph node cells and IgE in the serum were tested. Neither IL-4 or IgE was detected in OVA(mPEG)₁₁ treated rats by the assays used here suggesting that a systemic shift from Th1 type to Th2 type was not likely to be involved in the tolerance induced by treatment with OVA(mPEG)₁₁. Although production of IL-4 was not tested in splenocytes from OVA(mPEG)₁₁ treated rats because these transferred cells were injected without culture in vitro, it would be important

and interesting to investigate whether these splenocytes are able to produce immunoregulatory cytokines such as IL-4 or TGF-β.

Using the experimental protocol shown in Figure 1, it is not possible to establish unequivocally if cellular immunity is involved in the development of the disease, and if the inhibitory effects of treatment with OVA(mPEG)₁₁ affect mainly the cellular arm of the immune response. To shed some light on this question, we used a cell transfer system for determination of the involvement of cellular immunity. The development of disease, which was induced by transfer of OVA primed lymph node cells, was suppressed by co-transfer of splenocytes from OVA(mPEG)₁₁ treated rats (Fig 7). This evidence may be interpreted as indicating that splenocytes from rats, which had been treated with OVA(mPEG)₁₁, inhibited the manifestation of the disease which would have been induced by the exclusive transfer of OVA primed lymph node cells. Therefore, the proposed mechanism for induction of tolerance by pre-administration of antigen-mPEG conjugates postulates that antigen specific suppressor cells and/or their suppressive factors inactivate the corresponding antigen specific T helper cells.¹⁹ The data about suppression in the effector phase (Fig 7) might be interpreted as being that this suppression was effective at the challenge site, while the data during the induction phase (Figs 2 and 3) could be interpreted as being that this suppression was induced in the draining lymph nodes.

In conclusion, this study (i) confirms that successful induction of antigen specific tolerance may be achieved by antigen-mPEG conjugates, and (ii) extends this capacity of mPEG conjugates to suppression of antigen specific T cells as demonstrated by inhibition of the development of EC by these cells.

A Fukushima and K Nishino contributed equally to the study.

We should like to thank Professor Alec H Schon for his inspiration, helpful discussions, and critical editorial suggestions during the preparation of this manuscript; Professor Shigeyoshi Fujimoto and Dr Glen Lang for valuable suggestions; and Ms Natsuko Naruoka for technical help in the preparation of histological slides.

- Cobbold SP, Qin S, Leong LYW, et al. Reprogramming the immune system for peripheral tolerance with CD4+ and CD8+ monoclonal antibodies. *Immunol Rev* 1992;129:165–201.
- Nussenblatt RB, Caspi RR, Mahdi R, et al. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. *J Immunol* 1990;144:1689–95.
- Kuchroo VK, Greer JM, Kaul D, et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. *J Immunol* 1994;153:3326–36.
- Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. *Am J Ophthalmol* 1997;123:583–92.
- Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. *Science* 1993;259:1321–4.
- Chiller JM, Romball CG, Weigle WO. Induction of immunological tolerance in neonatal and adult rabbits. Differences in the cellular events. *Cell Immunol* 1973;8:28–39.
- Walters CS, Moorhead JW, Claman HN. Immunity and tolerance to hapten (NIP) coupled to an isologous carrier (mouse gamma globulin). *J Exp Med* 1972;136:546–55.
- Lee WY, Schon AH. Abrogation of reaginic antibodies with modified allergens. *Nature* 1977;267:618–9.
- Fukushima A, Yoshida H, Iwamoto H, et al. The role of cellular immunity both in the induction and effector phases of

- experimental allergic blepharo-conjunctivitis (EAC) in rats. *Exp Eye Res* 1997;**65**:631-7.
- 10 Yoshida H, Yoshida O, Iwamoto H, *et al.* Analysis of effects of stimulation in vitro of ovalbumin (OVA) primed lymph node cells on adoptive transfer of experimental immune-mediated blepharoconjunctivitis (EC) in Lewis rats. *Br J Ophthalmol* 1998;**82**:1189-94.
 - 11 Fukushima A, Nishino K, Yoshida O, Ueno H. Characterization of the immunopathogenic responses to ovalbumin (OVA) peptide 323-339 in experimental immune-mediated blepharoconjunctivitis (EC) in Lewis rats. *Curr Eye Res* 1998;**17**:763-9.
 - 12 Jackson CC, Charlton JL, Kuzminski K, *et al.* Synthesis, isolation and characterization of conjugates of ovalbumin with monomethoxypolyethylene glycol using cyanuric chloride as the coupling agent. *Anal Biochem* 1987;**165**:114-27.
 - 13 Roman E, Harris DP, Jurcevic S, *et al.* H-2-associated effects of flanking residues on the recognition of a permissive mycobacterial T-cell epitope. *Immunology* 1995;**86**:183-9.
 - 14 Mota I. On the site of rat reagin formation. *Immunology* 1966;**11**:137-40.
 - 15 Gery I, Waksman BH. Role of the thymus in tolerance: V. Suppressive effect of treatment with nonaggregated and aggregated bovine gamma-globulin on specific immune responses in normal adult rats. *J Immunol* 1967;**98**:446-60.
 - 16 Rauch HC. Modulation of adoptive cell transfers in experimental allergic encephalomyelitis by antigen treatment of donors. *Cell Immunol* 1981;**60**:220-7.
 - 17 Saoudi A, Kuhn J, Huygen K, *et al.* TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. *Eur J Immunol* 1993;**23**:3096-103.
 - 18 Kezuka T, Sakai J, Yokoi H, *et al.* Peptide-mediated suppression of experimental autoimmune uveoretinitis in mice: development of a peptide vaccine. *Int Immunol* 1996;**8**:1229-35.
 - 19 Bitoh S, Takata M, Maiti PK, *et al.* Antigen-specific suppressor factors of noncytotoxic CD8+ suppressor T cells downregulate antibody responses also to unrelated antigens when the latter are presented as covalently linked adducts with the specific antigen. *Cell Immunol* 1993;**150**:168-93.